Daily8d
Sacubitril/Valsartan Safe to Continue Even with GFR Below 30 ml/min in HF Patients: Research Finds
The PARADIGM-HF and PARAGON-HF trials demonstrated consistent benefits of sacubitril/valsartan relative to RAS inhibitors in ...
American College of Cardiology7d
Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses
In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...
Too Old to Operate6d
Racial Differences in Heart Failure Outcomes with Sacubitril/Valsartan
The following is a summary of “Impact of Race on Sacubitril/Valsartan use of HF,” published in the October 2024 issue of Cardiology by Lu et al. There is limited understanding of how self-reported ...
The American Journal of Managed Care27d
Posters Highlight Clinical Impact of, Prescription Barriers to Sacubitril/Valsartan
Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.